In today’s #ThursdayDiscovery we are highlighting the research from UK NEQAS ICC & ISH, featuring the use of digital image analysis and cell lines as aids in the development of a quantitative external quality assessment program for Ki-67. Ki-67 is a well-established biomarker of proliferation in breast cancer. However, the value of the prognostic information it provides to the treatment decision making process is hampered by a lack of analytical reproducibility despite much work to improve this. The study demonstrates how digital image analysis and cell lines can help laboratories achieve precise Ki-67 testing, aiding in better prognosis and treatment planning, especially for early-stage breast cancer patients. Read the study here: https://hubs.ly/Q02H2mxK0
Visiopharm
Forskning inden for bioteknologi
Hoersholm, Denmark 8.453 følgere
Visiopharm® is a world leader in AI-driven digital precision pathology software.
Om os
We are a leading provider of AI-driven precision pathology software for research and diagnostics. In research, we are a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, we are a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and and can be easily activated and integrated into existing lab workflows. Founded in 2002, we are privately owned and operate internationally with over 750 customer accounts in more than 40 countries. Our company’s headquarters are located in Denmark’s Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
- Websted
-
http://www.visiopharm.com
Eksternt link til Visiopharm
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 51-200 medarbejdere
- Hovedkvarter
- Hoersholm, Denmark
- Type
- Privat
- Grundlagt
- 2001
- Specialer
- Cancer Diagnostics, Cancer Research, Image Analysis, Stereology, Quantitative Digital Pathology, Biomarker Development, Tissue Micro Array (TMA) Management, Pathology, Tissue Section Alignment, Digital Pathology og Spatial biology
Beliggenheder
Medarbejdere hos Visiopharm
Opdateringer
-
Exciting times!
📣 We are excited to announce a strategic partnership with Visiopharm, a global leader in AI-driven precision pathology. This collaboration with Visiopharm helps us empower our clients in their search for the next breakthrough in biotechnology and medicine by transforming their pathology data into actionable insights. "Visiopharm is thrilled to strategically collaborate with Glint Lab, a forward-thinking CRO that shares our commitment to quality and innovation. By integrating our Oncotopix Discovery platform, Glint Lab will be able to offer their clients unparalleled precision and insights in tissue-based image analysis," said Jeni Caldara, Strategic Partnership Manager of Visiopharm. 👉 Read the news: https://wp.me/pfJUnQ-gd #Digitalpathology #ImageAnalysis #AI
-
Confused about which markers make up which phenotype of cell? Have a look at our immune oncology PD-L/1 landscape sheet: https://hubs.ly/Q02Fy4nK0 No matter your imaging system and plex level of your assay, Phenoplex has the solution for all spatial biology assays: fully automated phenotyping for up to 8 markers and user-guided phenotyping for 8-40+ markers. #SpatialBiology #Phenoplex #ImmuneOncology
Solutions for all plex levels - Visiopharm · Pathology image analysis software
https://visiopharm.com
-
✨ Customer Spotlight ✨ We sat down with Dr. Ken Pritzker, co-founder of Proteocyte AI, to delve into their innovative prognostic LTD test, Straticyte™. This digitally delivered oral cancer predictor, powered by Visiopharm analysis, represents a significant leap forward in early cancer detection and patient care. Straticyte can calculate the 5-year probability that dysplastic lesions will progress to cancer. It has a sensitivity of 96% and an NPV (negative predictive value) of 95%, and those are significantly higher than the values for histological dysplasia grading, which are 75% and 59% respectively. "The test is so good that if the Straticyte value is low, the patient can go back to live a normal life. But for cases with an elevated Straticyte value, those patients need to be watched closely and followed up against a possible recurrence or cancer. So compared to the current practice, Straticyte provides greater objectivity, sensitivity, and predictive power." - Dr. Pritzker. 👉 Read the full blog interview to learn more about this innovative approach and its impact on cancer diagnostics: https://lnkd.in/d9SYKmug
-
-
Masterclass this Wednesday - are you joining us? Dr. Janusz F. will present "HOST-Factor: Unveiling pancreatic cancer microenvironment neighborhoods through highplex imaging and spatial profiling." This talk will highlight the application of Visiopharm’s Phenoplex workflow and its Neighbor Counts module to identify and evaluate HOST+ CAF populations and their spatial distribution. Developed specifically for a pancreatic cancer clinical trial at Fox Chase Cancer Center, this user-friendly pipeline is flexible and useful for assessing diverse stromal compartments in distinct solid tumor cases. Date: July 17 @4PM CET, 10AM EST Register now: https://hubs.ly/Q02qxpLS0 #VisiopharmSpatialSeries
-
-
Congratulations to Rachel Pennie from the Scotland Institute of Cancer Research UK (CRUK) with her Poster "A global phenotyping method using artificial intelligence to overcome the cell segmentation bottleneck". It's great to see Visiopharm Deep Learning being used to enhance Multiplex Phenotyping 👏 If you are at the Spatial Biology Congress in The Hague, come by booth #2 to meet our team! #Phenoplex
-
-
Live at the Spatial Biology Congress in The Hague, Netherlands ✨ If you are attending the conference, meet our team at booth #2 to see a live demo of our newest spatial neighborhood capabilities in #Phenoplex. Be sure to explore poster #10 - we are presenting the HOST-Factor, an innovative approach developed by Janusz F., Edna (Eti) Cukierman, et al. at Fox Chase Cancer Center. See you there!
-
-
📣 We are thrilled to announce our strategic collaboration with Glint Lab, a California-based full stack precision pathology laboratory dedicated to preclinical and early-stage discovery. This collaboration with Visiopharm’s Oncotopix Discovery platform elevates Glint Lab’s end-to-end services, reinforcing their commitment to quality and transparency in scientific research. “Choosing Visiopharm’s Oncotopix Discovery was a clear decision for us at Glint Lab. Their advanced image analysis platform and unique data exploration tools perfectly align with our mission to deliver high-quality research services and enable our clients to explore tissue-derived data much deeper than they usually would. This partnership will significantly enhance our ability to support our clients’ scientific discoveries,” said Misagh Naderi, PhD, Chief Executive Officer of Glint Lab. 👉 Read the news: https://lnkd.in/g5NXcFcF #OncotopixDiscovery #StayCurious
Visiopharm announces collaboration with Glint Lab, Inc to enhance pathology solutions and drive scientific discovery - Visiopharm
https://visiopharm.com
-
Spatial Biology Masterclass Alert! 📣 We are excited to invite you to our upcoming masterclass with Dr. Janusz F. Franco-Barraza, Research Assistant Professor at Cukierman Lab and Manager at the Spatial Immuno-Proteomics Facility, Fox Chase Cancer Center. 🔍 Masterclass #4: HOST-Factor: Unveiling pancreatic cancer microenvironment neighborhoods through highplex imaging and spatial profiling. 📅 Date: July 17 @4PM CET, 10AM EST Join Dr. Franco-Barraza as he delves into the application of innovative research using the Harmonic Output of Stromal Traits (HOST) to evaluate the tumor microenvironment (TME). This talk will highlight the application of Visiopharm’s Phenoplex workflow and its Neighbor Counts module to identify and evaluate HOST+ CAF populations and their spatial distribution. Developed specifically for a pancreatic cancer clinical trial at Fox Chase Cancer Center, this user-friendly pipeline is flexible and useful for assessing diverse stromal compartments in distinct solid tumor cases. Register for the session now: https://hubs.ly/Q02qxpLS0 #VisiopharmSpatialSeries
-
-
We are excited to introduce the new spatial neighbourhood analysis tools in #Phenoplex, the latest iteration of our complete workflow for all your multiplex image analysis needs! Dr. Fabian Schneider, our Research Product Manager, provides a quick overview of these exciting new features in the video below. Attending the Spatial Biology Congress in The Hague this week? Visit us at Booth #2 and meet David Mason and Roberto Santamaría for a live demo of our spatial neighborhood capabilities. Learn more about the new release here: https://lnkd.in/gq8GcP-x #SpatialBiology #MultiplexImageAnalysis